{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:06:32Z","timestamp":1792202792892,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jneuroim.2022.577812","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T16:25:49Z","timestamp":1642091149000},"page":"577812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis"],"prefix":"10.1016","volume":"364","author":[{"given":"Gaurav","family":"Nepal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan Ariel","family":"Coghlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parash","family":"Rayamajhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jneuroim.2022.577812_bb0005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/dmcn.14336","article-title":"Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease","volume":"62","author":"Albassam","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0010","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0020","series-title":"Expert Opinion on Emerging Drugs","first-page":"75","article-title":"Emerging drugs for the treatment of adult MOG-IgG-associated diseases","volume":"vol. 26","author":"Carnero Contentti","year":"2021"},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577812_bb0025","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577812_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neuroinflammation"},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577812_bb0035","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol. [Internet]."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577812_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577812_bb0045","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577812_bb0055","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577812_bb0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol. [Internet]."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577812_bb0065","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody\u2013associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102376","article-title":"Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey","volume":"44","author":"Inan","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577812_bb0075","first-page":"1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflam. [Internet]"},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577812_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/WNO.0000000000000669","article-title":"Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"39","author":"Jelcic","year":"2019","journal-title":"J. Neuro-Ophthalmol."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577812_bb0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/14728222.2012.677438","article-title":"The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?","volume":"16","author":"Lee","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jneuroim.2022.577812_bb0090","first-page":"6","article-title":"Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: a meta-analysis","volume":"85","author":"Li","year":"2021","journal-title":"J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas."},{"issue":"10","key":"10.1016\/j.jneuroim.2022.577812_bb0095","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"10.1016\/j.jneuroim.2022.577812_bb0100","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1007\/s00415-020-09755-x","article-title":"MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation","volume":"267","author":"Loos","year":"2020","journal-title":"J. Neurol. [Internet]"},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577812_bb0105","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577812_bb0110","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577812_bb0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ane.13291","article-title":"Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis","volume":"142","author":"Nepal","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0120","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O\u2019Connell","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry. Engl."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577812_bb0125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.jneuroim.2022.577812_bb0130","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1073\/pnas.90.17.7990","article-title":"Myelin\/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex","volume":"90","author":"Pham-Dinh","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577812_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"October 2019","key":"10.1016\/j.jneuroim.2022.577812_bb0140","first-page":"2019","article-title":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","volume":"41","author":"Rigal","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577812_bb0145","first-page":"e1097","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology [Internet]"},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577812_bb0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577812_bb0155","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577812_bb0160","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102843","article-title":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.jneuroim.2022.577812_bb0175","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577812_bb0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2022.577812_bb0185","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis [internet]","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:40:24Z","timestamp":1759048824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572822000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"alternative-id":["S0165572822000078"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577812","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577812"}}